Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Ligand (LGND) Breakout! -- Ignore unavailable to you. Want to Upgrade?

To: JOHN W. who wrote (11155)	11/15/1997 12:46:00 PM
From: CYBERKEN	Respond to of 32384

I'd be interested in what you specifically don't like about the Lilly deal, since I was quite impressed with it. Also regarding burn rate: what's in the pipeline that you feel is assured of failure and thus can't be made the subject of future Lilly-like deals? Perhaps you can save this small investor some financial grief.

To: JOHN W. who wrote (11155)	11/15/1997 1:16:00 PM
From: Henry Niman	Read Replies (1) \| Respond to of 32384

JOHN, I have been posting on LGND since 1992, as most readers of this thread know. LGND has one of the best, if not the best pipelines in the industry. Their clinicals have been stellar and they have just signed a mega-deal with LLY to take them through a profitable 1999. The drugs that are being developed by their partners are moving through the clinic and LGND's own drugs have been about as good as possible. Robertson Stephens projected earnings of $14.55 by 2006 on a fully diluted 50 million shares, and they didn't expect profitability until 2000. LGND is a major player in some of the biggest markets and I expect long term investors to be all smiles.